These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 8522300)
21. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer. Li PX; Ngo D; Brade AM; Klamut HJ Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885 [TBL] [Abstract][Full Text] [Related]
22. Participation of p53 protein in the cellular response to DNA damage. Kastan MB; Onyekwere O; Sidransky D; Vogelstein B; Craig RW Cancer Res; 1991 Dec; 51(23 Pt 1):6304-11. PubMed ID: 1933891 [TBL] [Abstract][Full Text] [Related]
23. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243 [TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Kessis TD; Slebos RJ; Nelson WG; Kastan MB; Plunkett BS; Han SM; Lorincz AT; Hedrick L; Cho KR Proc Natl Acad Sci U S A; 1993 May; 90(9):3988-92. PubMed ID: 8387205 [TBL] [Abstract][Full Text] [Related]
25. p53 mutations in matched primary and metastatic human tumors. Peller S; Halevy A; Slutzki S; Kopilova Y; Rotter V Mol Carcinog; 1995 Jul; 13(3):166-72. PubMed ID: 7619219 [TBL] [Abstract][Full Text] [Related]
26. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856 [TBL] [Abstract][Full Text] [Related]
27. The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Attardi LD Mutat Res; 2005 Jan; 569(1-2):145-57. PubMed ID: 15603759 [TBL] [Abstract][Full Text] [Related]
28. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661 [TBL] [Abstract][Full Text] [Related]
29. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. D'Assoro AB; Busby R; Suino K; Delva E; Almodovar-Mercado GJ; Johnson H; Folk C; Farrugia DJ; Vasile V; Stivala F; Salisbury JL Oncogene; 2004 May; 23(23):4068-75. PubMed ID: 15064746 [TBL] [Abstract][Full Text] [Related]
30. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790 [TBL] [Abstract][Full Text] [Related]
31. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Ooe A; Kato K; Noguchi S Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082 [TBL] [Abstract][Full Text] [Related]
32. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Baptiste N; Friedlander P; Chen X; Prives C Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172 [TBL] [Abstract][Full Text] [Related]
33. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Wang S; El-Deiry WS Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705 [TBL] [Abstract][Full Text] [Related]
34. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Gatti L; Supino R; Perego P; Pavesi R; Caserini C; Carenini N; Righetti SC; Zuco V; Zunino F Cell Death Differ; 2002 Dec; 9(12):1352-9. PubMed ID: 12478472 [TBL] [Abstract][Full Text] [Related]
35. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426 [TBL] [Abstract][Full Text] [Related]
36. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53. Ghaleb A; Yallowitz A; Marchenko N Commun Biol; 2019; 2():436. PubMed ID: 31799437 [TBL] [Abstract][Full Text] [Related]
37. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Matsui SI; Arredondo MA; Wrzosek C; Rustum YM Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989 [TBL] [Abstract][Full Text] [Related]
38. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431 [TBL] [Abstract][Full Text] [Related]
39. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression. Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093 [TBL] [Abstract][Full Text] [Related]
40. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Marzec KA; Lin MZ; Martin JL; Baxter RC Oncotarget; 2015 Sep; 6(29):26583-98. PubMed ID: 26378048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]